NCT03254147 - Medical Need of OAC Reversal | Biotech Hunter

Enrollment

53,969

Participants

Timeline

Start Date

October 15, 2017

Primary Completion Date

October 30, 2017

Study Completion Date

November 10, 2017

Conditions

Atrial Fibrillation

Interventions

DRUG

warfarin

DRUG

dabigatran

Non-vitamin K dependent oral anti-coagulants (NOACs)

DRUG

Apixaban

Non-vitamin K dependent oral anti-coagulants (NOACs)

DRUG

Edoxaban

Non-vitamin K dependent oral anti-coagulants (NOACs)

DRUG

Rivaroxaban

Non-vitamin K dependent oral anti-coagulants (NOACs)

Trial Locations (1)

Nippon Boehringer Ingelheim Co., Ltd., Tokyo